A month has gone by since the last earnings report for Merck (MRK). Shares have added about 1.7% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to ...

Merck (MRK) announced plans to separate its core pharmaceutical division into two units as it prepares for the upcoming patent expiration of its top-selling drug. The drugmaker said it is organizing ...

Merck & Co., Inc. (NYSE:MRK) is one of the best immunotherapy stocks to buy according to hedge funds. On February 13, Merck & Co., Inc. (NYSE:MRK) was upgraded to Buy from Hold by Deutsche Bank, with ...

Merck reaches new high after earnings update, oncology restructuring, and clinical progress, highlighting position within the ...

Merck & Co. Inc. (NYSE:MRK) is one of the best value stocks to buy now. On February 19, Merck announced positive second-season findings from the Phase 3 SMART trial evaluating ENFLONSIA (clesrovimab) ...

TD Cowen 46th Annual Health Care Conference March 3, 2026 1:50 PM ESTCompany ParticipantsCaroline Litchfield - Executive ...

Merck (MRK) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of ...

Royal Bank Of Canada initiated coverage on Merck & Co., Inc.with an outperform rating The company reported quarterly revenue ...

Merck & Co., Inc. (NYSE:MRK) is included among the 16 Best Dividend Stocks with Rising Payouts. On February 13, Deutsche Bank analyst James Shin upgraded Merck & Co., Inc. (NYSE:MRK) to Buy from Hold.

Merck (MRK)’s stock surged by 41% in the last six months, driven not only by a modest revenue increase but also by a significant profit jump and heightened investor confidence. The factors behind this ...